ST. LOUIS, Oct. 2, 2025 — Gershman Investment Corp. provided construction and permanent financing for Mansion House Apartments in St. Louis, MO. Managing Director Chris Will originated a $78 million dollar HUD 221(d)4 loan for this historic 29-story high-rise tower. Adjacent to the Gateway Arch, with 415 apartments units, Mansion House is one of St. Louis’s most iconic riverfront properties. Renovations to the 1960’s-era building will take less than two years to complete, with fully modernized units being delivered in 2027. The $195 million dollar investment represents one of the largest residential investments Downtown St. Louis has seen in decades, and will mark a new chapter in the life of this historic property.
In addition to the HUD-insured debt provided by Gershman, sources of funding include State and Federal Historic Tax Credits, Opportunity Zone capital from Catalyst Opportunity Funds, and gap financing from Arch to Park Equity Fund. Real estate tax-abatement and sales tax exemption on construction materials was provided by The City of St. Louis.
The $78 million GNMA-backed HUD 221(d)4 provided 40-year fixed, non-recourse, construction – permanent debt. Gershman’s GNMA security was acquired by The Builder’s ProLoan Bond Fund, a pension fund whose members include various labor trade unions. The Fund provided a significantly below-market interest rate.
The FHA 221(d)(4) Substantial Rehabilitation loan is a government-insured financing program designed to fund the purchase and major renovation of multifamily rental properties. It provides long-term, fixed-rate, non-recourse financing that covers both construction costs and permanent debt in a single loan.
Gershman Investment Corp. is one of the nation’s few independently owned mortgage companies that offer FHA-insured multifamily and healthcare financing. Our extensive history of 70 years of personal service, expertise, and dedication to problem-solving ensures a smooth process for financing of project loans. We rank among the top ten originators of FHA multifamily programs by the US Department of Housing and Urban Development. We are one of a small, select group of lenders nationwide to be HUD-approved for MAP (Multifamily Accelerated Processing) for apartments and LEAN processing for nursing homes and assisted living facilities. For more information about Gershman Investment Corp., please visit www.gershmaninvestmentcorp.com.
7800 Forsyth Blvd, Suite 700, St. Louis, MO 63105 | (314) 889-0600
Partnership to Accelerate Job Creation and Innovation in AI, Robotics, and Supply Chain as part of two NJEDA Investment programs.
NEW YORK, Oct. 2, 2025 —Interwoven Ventures (Interwoven), an early-stage venture capital firm specializing in robotics and artificial intelligence (AI), has been selected by the New Jersey Economic Development Authority (NJEDA) to co-invest through the New Jersey Innovation Evergreen and Venture Fund Investments Programs. The Partnership will channel capital and expertise into New Jersey startups driving innovation in manufacturing, logistics, healthcare and transportation.
Interwoven Ventures invests and advises founders, startups, universities and centers of innovation on AI’s transformative impact across industries particularly within manufacturing, logistics, transportation, and healthcare. Interwoven brings guidance and expertise in driving operational efficiencies, automation, and innovation—particularly in areas like predictive analytics and AI-powered diagnostics.
“New Jersey is a magnet for bold entrepreneurs, and we’re proud to partner with NJEDA to help founders scale,” said Erez Agmoni, co-founder and General Partner of Interwoven Ventures. “At Interwoven, we don’t just write checks, we bring decades of operational experience, a deep industry network, and hand-on guidance in AI and Robotics. The collaboration gives startups in New Jersey access to both capital and know-how to turn breakthrough ideas into lasting business.”
“Under Governor Murphy’s leadership, the New Jersey Innovation Evergreen Fund has empowered high-potential startups by establishing a self-sustaining investment cycle that attracts capital,” said NJEDA Chief Executive Officer Tim Sullivan. “Through the funding of Qualified Venture Firms such as Interwoven Ventures, this innovative program is fueling the growth of businesses, reinforcing New Jersey’s standing as a premier global hub for innovation.”
Whether you’re a founder building the next breakthrough in AI and Robotics, an investor looking to co-invest in frontier technologies, or an innovation partner shaping the future of New Jersey’s economy, we invite you to connect with Interwoven Ventures at www.interwoven.vc .
About Interwoven Ventures Interwoven Ventures is an early-stage venture capital firm specializing in robotics and AI, with a focus on transformative opportunities in industries like manufacturing, logistics, transportation, and healthcare. Since its inception in 2022 as an incubated venture of ROBO Global, the firm has been committed to leveraging decades of industry and operational expertise to empower visionary entrepreneurs and build a foundation for long-term success and innovation. For more information, please visit interwoven.vc.
About the NJEDA The New Jersey Economic Development Authority (NJEDA) serves as the State’s principal agency for driving economic growth. The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy. Through partnerships with a diverse range of stakeholders, the NJEDA creates and implements initiatives to enhance the economic vitality and quality of life in the State and strengthen New Jersey’s long-term economic competitiveness.
One of few Reg A+ raises in history to surpass $70M; Pacaso’s total equity funding now tops $300M as demand surges for luxury co-ownership
SAN FRANCISCO, Oct. 2, 2025 — Pacaso, the tech-enabled marketplace for co-owned luxury vacation homes, today announced the close of its record-setting SEC-qualified Regulation A+ growth round, raising over $72.5 million from more than 17,500 individual investors. ¹ Pacaso’s raise is the largest real estate Reg A+ offering of 2025 and one of only a handful of companies in history to surpass $70 million, cementing the company as one of the most significant Reg A+ issuers to date. The milestone brings Pacaso’s total equity funding to more than $300 million and highlights growing demand for access to real estate and early-stage equity opportunities.
“This raise was proof that thousands of people believe in a better, smarter way to own and experience a vacation home,” said Austin Allison, co-founder and CEO of Pacaso. “The overwhelming demand exceeded expectations, showing that co-ownership is more than a trend — it’s a movement. By combining the power of community with institutional support, we’re making luxury ownership more attainable and more meaningful for families and investors around the world.”
Pacaso’s raise was powered by DealMaker, whose capital-raising platform enabled the company to scale its community-first campaign to tens of thousands of prospective investors.
“This deal is a perfect example of how retail investors can be a valuable source of funding for high-growth companies in conjunction with institutional and venture capital,” said Rebecca Kacaba, co-founder and CEO of DealMaker. “We’re proud to have helped Pacaso engage such a broad base of individual investors in this investment round — fueling future growth while giving those investors a unique opportunity to be part of something transformative.”
Pacaso’s record raise builds on several recent milestones:
Institutional validation: Pacaso recently secured a $100 million credit facility with Texas Capital to launch the industry’s first mortgage purpose-built for co-ownership.
Operational strength: The company reported $12.6 million in adjusted gross profit in the first half of 2025, with improving margins and reduced cash burn. ²
Growth trajectory: Pacaso has facilitated more than $1.2 billion in transactions and service fees to date, ³ generated over $138 million in lifetime gross profit, ² and expanded into 40+ destinations across the U.S., Mexico, and Europe, with 10 new international market listings including London, Paris, Italy, and the Caribbean.
Pacaso’s $72.5 million Reg A+ raise is the largest real estate offering of 2025. It is nearly five times the SEC’s historical average of about $12.5 million, 4 and few Reg A+ issuers in any sector cross the $30 million mark. 5
“Pacaso is proud to have led one of the most significant Reg A+ raises in history,” said Tom Mulholland, Head of Strategic Initiatives and Capital Development at Pacaso. “By welcoming thousands of retail investors to join our mission, we’re broadening access to an opportunity once limited only to institutions. This outcome underscores the confidence in our vision and expands the Pacaso community in several powerful ways.”
Founded in 2020 by tech entrepreneurs Austin Allison and Spencer Rascoff, Pacaso is the global co-ownership category leader, enabling buyers to co-own luxury vacation homes in top destinations worldwide. The company offers ownership shares ranging from one-eighth to one-half, paired with flexible financing, professional management, turnkey design, and full-service support that includes scheduling, maintenance, and resale assistance. Pacaso also leverages AI-powered tools to scale operations and enhance the owner experience.
About Pacaso Co-founded by Austin Allison and Spencer Rascoff in 2020, Pacaso® is a technology-enabled marketplace that modernizes real estate co-ownership, enabling families to effortlessly own a luxury vacation home and travel with confidence. Pacaso curates private residences in premier destinations across the U.S. and internationally, with exceptional amenities, luxury interiors and expert design. After purchase, Pacaso professionally manages the home, provides white-glove scheduling and personalized service, and ensures seamless resale.
¹ Investor participation. Based on internal company records as of September 2025.
² We calculate Adjusted Gross Profit as gross profit under GAAP adjusted for amortization of developed technology, inventory valuation adjustment in the current period, inventory valuation adjustment in prior periods, impairments and write-offs and share-based compensation. Inventory valuation adjustment in the current period is calculated by adding back the inventory valuation adjustments recorded during the period on homes that remain in inventory at period end. Inventory valuation adjustment in prior periods is calculated by subtracting the inventory valuation adjustments recorded in prior periods on homes sold in the current period. Additionally, we calculate Adjusted Gross Profit Excluding Impact of Whole Homes, which is an indication of the performance of our core business offering of selling and managing co-owned real estate and is a useful measure of the volume of transactions that flow through our platform in a given period. We view this metric as an important measure of business performance, as it captures gross profit performance related to units transacted in a given period and provides comparability across reporting periods.
3 We define Gross real estate transacted and associated service fees, excluding whole home sales, as the total dollar value, less any concessions, of co-ownership transacted during the period, which includes co-ownership real estate sales, gain from real estate investments presented gross, real estate services, and the applicable margin on such transactions. We view this metric as an indication of the performance of our core business offering of selling co-owned real estate and is a useful measure of the volume of transactions that flow through our platform in a given period, which ultimately impacts gross profit.
4 Historical averages: SEC Division of Economic and Risk Analysis, Regulation A and Regulation Crowdfunding Offerings: 2025 Update, June 2025. The report notes Tier 2 Regulation A issuers raised an average of about $12.5 million from 2015 through 2024 across more than 1,400 offerings.
5 Market comparison. Based on external industry research and publicly available issuer filings. The SEC does not publish average raise sizes by vertical; this comparison reflects aggregated data on real estate-focused Reg A+ campaigns.
Certain statements in this release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding Pacaso’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Readers are cautioned not to put undue reliance on forward-looking statements, and Pacaso assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Pacaso does not give any assurance that it will achieve its expectations.
In addition to financial results presented in accordance with generally accepted accounting principles, this press release may contain financial measures that do not conform to U.S. GAAP if we believe they are useful to investors or if we believe they will help investors to better understand our performance or business trends. Reconciliations of these non-GAAP financial measures to the nearest comparable GAAP measures are included in our Offering Statement, which may be obtained from: invest.pacaso.com.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE.
Following $40M Series B, CertifyOS launches Provider Hub to unify provider data into a single source of truth for health plans and digital health companies
NEW YORK, Oct. 2, 2025 — CertifyOS, the provider data intelligence company, today announced the launch of Provider Hub, its Provider Data Management (PDM) solution—the only end-to-end platform offering a unified, real-time, 360-degree view of every provider in a healthcare organization’s network.
Inaccurate provider data creates friction across nearly every function of a health plan. It harms member experience, delays payments, and increases compliance risk under mandates like the No Surprises Act and the Transparency in Coverage Rule. Despite its central role in operations, provider data has long been managed through siloed systems, spreadsheets, and outdated tools that can’t keep up with today’s demands.
“Unlike calcified legacy systems or traditional PDM solutions that don’t integrate with other systems, require costly IT resources, and take months or years to implement, CertifyOS takes a fundamentally different approach,” said Anshul Rathi, founder and CEO of CertifyOS. “We don’t digitize old workflows—we replace them. Because we are a data company at heart, we enable organizations to go from storing data to unlocking its enterprise-wide potential. This is the infrastructure healthcare needs, and the future we’ve been building toward since day one.”
CertifyOS’s Provider Hub ingests, cleanses, normalizes, and validates data from a wide range of sources—including credentialing, directories, claims, rosters, and internal systems—to power critical workflows that sit on top of this data and deliver operational insights across an enterprise. This reduces manual effort and leads to fewer silos, fewer vendors, fewer delays, and lower costs. The company already has multiple signed deals with customers seeking to address persistent pain points like credentialing delays, data duplication, and compliance risk.
An AI-Powered, Transparent, and Flexible Provider Data Backbone
As a continuously updated source of truth, CertifyOS’s solution enables organizations to improve data accuracy, drive system-wide intelligence, and reliably scale automation and AI. According to Gartner, 85% of AI projects fail—often due to poor data quality. CertifyOS’s platform provides the trusted foundation needed.
The solution is built to meet health plans where they are today and help transform operations for the future. It can:
Ingest and unify provider data from structured and unstructured sources into a single, complete profile.
Clean, standardize, and validate data using thousands of rules and 1,600+ primary sources.
Resolve duplicates and link records across systems using AI-driven logic to maintain data integrity.
Set and apply custom rules to prioritize the most authoritative or recent data when conflicts arise.
Model complex relationships between providers, groups, locations, and plans, with full audit trails.
Integrate directly with downstream systems including credentialing, contracting, directories, and claims.
Activate insights across departments to identify gaps, flag issues, and support decision-making.
Run credentialing, monitoring, and outreach workflows in real time to reduce turnaround and touchpoints.
Continuously monitor provider data and deliver alerts on expirations, sanctions, or outdated records.
“Every function inside a health plan touches provider data, yet most still operate on outdated tools that weren’t designed for today’s complexity,” added Rathi. “What makes this platform different is its ability to serve as a single foundation across departments. It enables better performance across claims, compliance, directories, and provider experience—not by patching existing systems, but by fixing the root issue. When provider data is reliable, everything downstream runs better. That’s the transformation this platform enables.”
About CertifyOS CertifyOS is the architect of modern provider data infrastructure — combining best-in-class technology, best-in-class data, and deep domain expertise to transform how healthcare operates. Entering the market in 2021 as a credentialing platform, CertifyOS now powers the full provider data lifecycle through a continuously updated source of truth powered by thousands of primary sources and available through one API. The provider data intelligence company is backed by esteemed investors including Transformation Capital, General Catalyst, Upfront Ventures, and SemperVirens. For more information, please visit us at CertifyOSos.com.
GÖTTINGEN, Germany, Oct. 2, 2025 — German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy. The therapy repairs cardiac function and holds the potential to significantly improve quality of life in patients with advanced heart failure by engrafting lab-engineered cardiac cell sheets to the surface of a damaged ventricle. This approach is currently being tested in a Phase 1/2 clinical study in Germany. Recruitment for the interim analysis of the Phase 2 was completed recently. Preclinical outcomes were published in the journal Nature earlier this year.
Led by Bioventure Management GmbH and strategic co-investor Satorius AG, the financing will enable the transition to a European Phase 3 registration trial and the scaling of GMP (Good Manufacturing Practice) production in collaboration and with know-how from Satorius AG. Erik Hoppe, Ph.D., Managing Director of Bioventure, said: “Repairon stands for visionary research with social relevance. The company has the potential to fundamentally change the treatment of heart failure.” Lothar Germeroth, Ph.D., CEO of Repairon, added that “the engineered heart muscle offers the prospect of reversing the course of congestive heart failure and significantly improving quality of life. For the first time, we see the opportunity to treat a previously incurable and expensive disease causally – with real global benefits for both patients and healthcare systems.”
The approach to repair damaged heart muscle with lab-produced heart tissue sheets is based on more than 30 years of research led by Wolfram-Hubertus Zimmermann, MD, Ph.D., professor and director of the Institute of Pharmacology and Toxicology at the University Medical Center Goettingen (UMG) in Northern Germany. Repairon, UMG, and the German Center of Cardiovascular Research (DZHK) collaborate closely on the development of this technology.
High medical need in advanced heart failure: Approximately 5% of the population in Germany suffers from chronic heart failure of any severity, and it is the third most common cause of death in this country. In the US, heart failure represents the most common cause of hospitalization and mortality in the senior population, and over 6 million people are affected. As the heart failure progresses to advanced stages, patients experience weakness with discomfort during all physical activities and at rest, sometimes even requiring constant bed rest. For these severely ill patients, the only treatment options currently available are mechanical pump devices or heart transplantation.
About Repairon: Repairon GmbH is a German biotech company based in Göttingen, Germany, focused on developing regenerative cell therapies for cardiac medicine. The company was founded in 2014 based on research by Wolfram-Hubertus Zimmermann, MD, Ph.D. and his team at the University Medical Center Goettingen, who have developed several tissue engineering technologies with proven applicability for organ repair and drug development. Repairon’s lead therapeutic candidate, the human engineered heart muscle sheet, is currently being evaluated in the BioVAT-HF Phase 2 clinical trial as a biological ventricular support tissue for end-stage heart failure.
About Bioventure: Founded in 2001, Bioventure has evolved from a specialized consulting firm into a successful investor in life science companies. Its focus is on companies with the potential to achieve measurable improvements in healthcare through biomedical innovations. Its investment model is based on exclusive financing vehicles (club deals), allowing wealthy entrepreneurial families and family offices to participate in promising individual projects. Bioventure’s active support – from selection and strategic development to exit – has led to the distribution of more than €100 million to investors. Successful exits with company valuations in the hundreds of millions to billions of euros underscore Bioventure’s expertise in scaling high-growth startups.
REDWOOD CITY, Calif., Oct. 2, 2025 — CrateDB, the real-time database for analytics, search, and AI across any data, today announced the appointment of Robert Ekstrom as Chief Executive Officer. Ekstrom’s arrival marks a major milestone for the company as it accelerates its growth trajectory and deepens its commitment to customers worldwide. Alongside this strategic leadership move, CrateDB also welcomes Gregor Bauer as Vice President of Customer Engineering.
Robert Ekstrom, CEO
Robert Ekstrom
Gregor Bauer
With more than two decades of experience leading global technology organizations, Robert Ekstrom has consistently demonstrated a unique ability to scale companies at the intersection of data, cloud, and analytics. He has built and led high-performing teams across international markets, guided product innovation, and successfully aligned technology strategies with business outcomes.
At CrateDB, Ekstrom will focus on expanding global adoption, strengthening the company’s position as the leading real-time database for analytics, search, and AI, and steering innovation to meet the growing demand for scalable data platforms. He succeeds Lars Färnström, bringing a fresh vision and a track record of execution at a critical moment in CrateDB’s journey.
“CrateDB has built an outstanding technology with immense market potential,” said Robert Ekstrom. “The ability to deliver real-time insights at scale is becoming mission-critical for enterprises across industries. I am excited to lead the company into its next phase, expanding our impact, and ensuring our customers can innovate faster with data.”
Gregor Bauer, VP of Customer Engineering
Joining Ekstrom on the leadership team is Gregor Bauer, an experienced technical leader in customer engineering and enterprise support. Bauer has led global solution engineering and customer success functions, helping organizations adopt and scale advanced data and analytics technologies. At CrateDB, he will lead the customer engineering organization, ensuring enterprises achieve rapid success and long-term value with the platform.
“Gregor brings a strong mix of technical depth and customer focus,” added Ekstrom. “As we expand, his leadership will be critical to ensuring our customers are not only supported but empowered to innovate.”
About CrateDB
CrateDB is a distributed SQL database that brings together analytics, search, and AI in real time. It ingests data from any source (streams, operational databases, warehouses, or files) and makes it instantly available for dashboards, BI tools, AI models, and applications. Unlike specialized databases that force trade-offs, CrateDB unifies structured, semi-structured, and unstructured data in one scalable system, delivering faster insights at a lower cost. Learn more at cratedb.com.
$75m funding round will fuel mission to protect financial institutions and consumers from fraud and scams
LISBON, Portugal, Oct. 2, 2025 — Feedzai, the leading AI-native RiskOps platform for financial crime prevention, today announced it is valued at more than $2 billion following an investment round of approximately $75 million. The new funding adds new institutional investors Lince Capital, Iberis Capital, and Explorer Investments, with renewed backing from Oxy Capital and Buenavista Equity Partners.
“Fraud isn’t just numbers on a balance sheet. It’s families losing their life savings and businesses losing customers. Protecting people and organizations from financial crime is why we built Feedzai. It’s our steadfast mission to keep commerce safe,” said Nuno Sebastião, Co-Founder and CEO of Feedzai. “This new investment round enables us to continue driving innovation to defend against whatever comes next, so that every form of payment, even those yet to be imagined, can be trusted and adopted safely.”
Company Momentum
Feedzai’s evolution into a comprehensive financial crime prevention platform for fraud, risk, and anti-money laundering teams has fueled strong growth. Feedzai protects more than 70 billion in annualized payment volume across card transactions and bill payments.
The new investment follows a year of rapid growth and innovation marked by major milestones:
Breakthrough products: Launched Feedzai Orchestration and Feedzai IQ, empowering financial institutions to make more intelligent, rapid, and precise risk assessments.
Customer impact: Doubled outcomes to more than $2B in losses prevented and 20M+ analyst hours saved.
Responsible AI leadership: Introduced the TRUST Framework, embedding responsible design into every facet of GenAI development so systems remain fair, explainable, and secure.
Multi-Product Platform for Fighting Financial Crime
The average financial institution uses disparate tools from up to a dozen different vendors to run its daily financial crime operations. This fragmented approach creates unnecessary complexity and inefficiency, especially as companies grow. Feedzai addresses this challenge by providing a comprehensive financial crime prevention solution that consolidates various point products into a single, modern platform and is increasingly powering more of the financial tech stack within companies as they transition from legacy systems to AI-native systems.
Feedzai’s platform has expanded to cover distinct financial institution product lines, including bank account openings, credit card transactions, transaction monitoring, payments, and more.
“Feedzai’s ability to execute across multiple product lines while scaling globally places them in the elite tier of software companies,” said Vasco Pereira Coutinho, CEO at Lince Capital. “Financial fraud is one of the defining risks of our time, and Feedzai combines proven technology with deep expertise to protect both banks and their customers. With its AI-driven, end-to-end approach to risk operations, Feedzai is uniquely positioned to transform the industry.”
Garrigues served as legal counsel to Feedzai on the recent investment round.
About Feedzai
Feedzai is the world’s first end-to-end financial crime prevention platform, protecting people and payments with AI-native solutions that stop fraud and financial crime. Leading financial institutions trust Feedzai to manage critical risk and compliance processes, safeguarding trillions of dollars of transactions while improving the customer experience and protecting the privacy of everyday users. For more information, users can visit feedzai.com.
ROCKVILLE, Md., Oct. 2, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company’s co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital.
OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng. By leveraging deep expertise in immuno-oncology and translational medicine, the Company has built a broad pipeline of innovative therapies with first-in-class or best-in-class potential. The proceeds from the Series B financing will primarily be used to support the advancement of the clinical development of the Company’s pipeline programs.
“Our Series B financing round progressed rapidly, and we deeply appreciate our investors’ recognition of our Company and continual support,” said Dr. Yang Liu, Co-Founder, Chairman of the Board, CEO and CSO of OncoC4. “We are committed to rigorously advancing the global development of our core pipeline, while strategically expanding business development activities, with the ultimate goal of delivering more disruptive therapies to patients worldwide.”
About OncoC4
Based in Rockville, Maryland, OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4’s pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases.
Strategic integration fuels Asabys’ goal to build a beyond €1 billion life sciences investment platform in Europe by 2030
Asabys incorporates Aliath Bioventures’ experienced team with a successful track record
Alta Life Sciences Spain I FCR fund to be co-managed by Asabys and AltamarCAM
MADRID and BARCELONA, Spain, Oct. 2, 2025 — Asabys Partners, a Spanish venture capital firm specialized in healthcare, and AltamarCAM Partners, a global investment firm specialized in private markets, have today agreed to integrate Aliath Bioventures (formerly Alta Life Sciences), AltamarCAM’s life sciences team, into Asabys and to jointly co-manage the Alta Life Sciences Spain I FCR fund. With the strategic unification, Asabys’ assets under management will expand from €300 million to over €400 million, significantly boosting its investment capacity, generating synergies, and ensuring continuity in creating value for investors.
The combination establishes a leading investment platform in Europe’s competitive life sciences sector. Asabys aims to surpass €1 billion in assets under management by 2030 to invest across market gaps that span tech transfer, company creation, scale-ups, and growth stage ventures. Since its establishment in 2018, Asabys has invested in 18 companies across biopharma, medtech, and digital health, and has had 2 successful exits. The combined team plans to launch new life sciences funds across diverse market segments and deepen collaboration going forward.
The investment teams from both firms have collaborated for many years and co-invested in Deepull, Ona Therapeutics, and Inbrain Neuroelectronics. United by a shared vision and complementary approach, this combination strengthens capabilities and creates synergies amid a consolidating, complex market. Companies in the Alta Life Sciences Spain I FCR fund continue to perform well and will be supported by Asabys going forward. Future plans include the launch of a new fund in early 2026, alongside other strategic healthcare funds, to accelerate expansion and build its leadership to become one of the largest life-science GPs in Southern Europe.
“The strategic integration of Aliath Bioventures represents a fantastic opportunity to increase our team and capabilities, accelerating our plans to support the full investment spectrum, investing in the best companies from inception to growth,” saidJosep Ll. Sanfeliu, Co-Founder and Managing Partner at Asabys Partners.
Clara Campàs, Co-Founder and Managing Partner at Asabys Partners, commented:“With Aliath and AltamarCAM, we share a similar investment outlook, scientific rigor, and a long-term commitment to founders. The addition of the Aliath team brings deep sector expertise, a proven track record, and a shared entrepreneurial mindset that will strengthen our ability to support the next generation of healthcare innovators.”
As part of the agreement, the Alta Life Sciences Spain I FCR fund will be co-managed by both Asabys and AltamarCAM. Asabys’ founding partners, Clara Campàs and Josep Sanfeliu, will join the Fund’s Investment Committee. The Aliath Bioventures team will be fully integrated into Asabys, with Montserrat Vendrell and José María Fernández becoming partners at the firm.
José Luis Molina, Global CEO of AltamarCAM Partners, remarked: “Privatemarkets are undergoing a consolidation phase where success depends on building first-class technical teams and scaling them effectively to maximize investment outcomes. From this perspective, we believe this amalgamation is the best possible way to carry out our management activity in this sector and to continue generating value in the portfolio of the Alta Life Sciences Spain I fund, which, while solid, requires additional time and resources to achieve its target return, which remains our main priority.”
About Asabys Partners
Asabys Partners is a venture capital firm specialized in the healthcare sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, with Alantra as a shareholder and Banc Sabadell as anchor investor. With close to €300 million in AUM and 18 portfolio companies (+2 divestments), Asabys invests in highly innovative and disruptive companies addressing unmet medical needs in the biopharmaceutical and healthtech verticals.
About AltamarCAM Partners
AltamarCAM Partners is a global investment firm focused on private markets, with the primary objective of providing institutional investors —including insurance companies, pension funds, and financial institutions— as well as high-net-worth individuals, with efficient access to investment in unlisted markets: private equity, venture capital, life sciences, real assets (real estate and infrastructure), and private debt/credit. The firm does so through a selection of international managers and by accessing them via various strategies (primary, secondary, co-investments, and direct investments).
With offices in Madrid, Cologne, Barcelona, New York, London, Santiago de Chile, and Munich, AltamarCAM Partners has a team of around 300 people and more than €20 billion in committed capital from investors.
